AlzeCure Pharma AB (publ) (STO:ALZCUR)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.470
+0.090 (6.52%)
Apr 30, 2026, 12:06 PM CET
Market Cap168.92M -23.2%
Revenue (ttm)n/a
Net Income-47.65M
EPS-0.47
Shares Out114.91M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume71,083
Average Volume114,660
Open1.380
Previous Close1.380
Day's Range1.380 - 1.600
52-Week Range1.300 - 4.950
Beta0.01
RSI46.00
Earnings DateApr 8, 2026

About AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 10
Stock Exchange Nasdaq Stockholm
Ticker Symbol ALZCUR
Full Company Profile

Financial Performance

Financial Statements

News

AlzeCure Pharma AB Transcript: Status Update

Orphan drugs are a rapidly growing, high-value segment, driven by unmet needs and strong incentives. ACD 440, a topical TRPV1 antagonist, targets erythromelalgia—a rare, severe pain disorder—with promising clinical results and orphan designation, positioning it for out-licensing and global commercialization.

8 months ago - Transcripts

AlzeCure Pharma AB Transcript: Study Update

ACD440, a topical TRPV1 antagonist gel, has shown significant pain reduction and strong safety in phase Ib and IIa studies for neuropathic pain with thermal hypersensitivity. The product offers local, predictable relief, can be combined with other treatments, and targets a large, growing market with high unmet need.

1 year ago - Transcripts